宁波美诺华药业股份有限公司 独立董事工作制度 第一章 总 则 第一条 为进一步完善宁波美诺华药业股份有限公司（以下简称"公司"） 的法人治理结构，促进公司规范运作，根据《中华人民共和国公司法》《上市公 司治理准则》《上市公司独立董事管理办法》（以下简称《管理办法》）《上海 证券交易所股票上市规则》（以下简称《股票上市规则》）《上海证券交易所上 市公司自律监管指引第 1 号——规范运作》（以下简称《规范运作指引》）等法 律、法规、规范性文件以及《宁波美诺华药业股份有限公司章程》（以下简称《公 司章程》）的相关规定，制定本制度。 第二条 公司独立董事是指不在公司担任除董事外的其他职务，并与公司及 其主要股东、实际控制人不存在直接或者间接利害关系，或者其他可能影响其进 行独立客观判断关系的董事。 第三条 公司独立董事占董事会成员的比例不得低于三分之一，且至少包括 一名会计专业人士。 公司董事会下设战略、薪酬与考核、审计、提名等专门委员会，独立董事应 当在审计委员会、提名委员会、薪酬与考核委员会成员中过半数，并担任召集人。 审计委员会成员应当为不在公司担任高级管理人员的董事，并由独立董事中 会计专业人士担任召集人。 ...

Core Points - The article outlines the investor relations management system of Ningbo Meinuo Pharmaceutical Co., Ltd, emphasizing the principles of fairness, openness, and integrity in communication with investors [1][2] - The company establishes a structured approach to investor reception and promotion, detailing the responsibilities of the board secretary and the securities affairs department [1][2] Group 1: General Principles - The company aims to enhance investor relations management and improve corporate governance by adhering to principles such as fairness, honesty, confidentiality, and efficiency [1][2] - The company prohibits unauthorized personnel from representing the company in investor relations activities, ensuring that only trained individuals participate [2] Group 2: Reception and Promotion Content - The company targets various stakeholders for its reception and promotion activities, including securities analysts, institutional investors, major shareholders, and media personnel [2][3] - Multiple communication channels are utilized, including the company website, stock exchange platforms, and investor education bases, to facilitate engagement with investors [3][4] Group 3: Communication and Disclosure - The company is committed to maintaining transparency by not disclosing any undisclosed significant information during communications with investors [4][5] - A detailed record-keeping system is established for all investor interactions, including the documentation of discussions and materials provided [5][6] Group 4: Compliance and Accountability - The company mandates that all investor-related activities be documented and that any violations of the established protocols will result in accountability for the involved parties [6][6] - The board of directors is responsible for interpreting the investor relations management system, which will take effect upon approval [6][6]

转债代码：113618 转债简称：美诺转债 宁波美诺华药业股份有限公司 证券代码：603538 证券简称：美诺华 公告编号：2025-095 关于修订、制定公司部分管理制度的公告 根据《中华人民共和国公司法》 《中华人民共和国证券法》 引》等有关法律、法规和规范性文件的最新规定，结合公司实际经营管理情况， 董事会同意修订、制定公司部分管理制度。具体情况如下： 《上市公司章程指 序号 修订的管理制度名称 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁波美诺华药业股份有限公司(以下简称"公司")于 2025 年 8 月 26 日召开 第五届董事会第十六次会议，审议通过了《关于修订、制定公司部分管理制度的 议案》。 序号 制定的管理制度名称 具体内容详见公司于上海证券交易所网（www.sse.com.cn）等指定信息披露 媒体同日披露的公司相关管理制度。 宁波美诺华药业股份有限公司 董事会 上述管理制度的修订、制定已经公司第五届董事会第十六次会议审议通过， 其中第 1—10 项、第 28 项制度尚需提交公司股东大会审议,其余制度 ...

Core Viewpoint - The document outlines the information disclosure management system of Ningbo Meinuo Pharmaceutical Co., Ltd, emphasizing the importance of accurate, timely, and fair disclosure of information that may impact stock trading prices [1][2]. Group 1: Information Disclosure Management - The company establishes a system to regulate the information disclosure behavior of its board members and senior management, ensuring compliance with relevant laws and regulations [1]. - Information that may affect stock trading prices includes periodic reports, temporary announcements, financial summaries, and other significant matters that are prepared but not yet disclosed [1][2]. - The board of directors leads the information disclosure work, with the board secretary responsible for handling external information publication [1][2]. Group 2: Confidentiality and Insider Information - Board members and senior management are required to maintain confidentiality regarding undisclosed significant information and are prohibited from leaking such information before it is publicly disclosed [2][3]. - There are strict rules against insider trading and market manipulation, with board members and senior management not allowed to disclose any undisclosed periodic reports or temporary announcements [2][3]. - The company has established a system for insider information knowledge, ensuring that those privy to undisclosed information adhere to confidentiality obligations [2][3]. Group 3: Approval and Reporting Process - Any external documents that need to be published must be submitted to the securities affairs department for review and approval by the board secretary before release [2][3]. - The company must refuse to submit annual statistical reports from external units that lack legal basis, while ensuring that any legally required submissions are documented and approved [3][4]. - External units or individuals are prohibited from disclosing any undisclosed significant information obtained through legal reporting requirements [4][5]. Group 4: Compliance and Accountability - The company mandates strict adherence to the information disclosure management system by all departments and subsidiaries, holding them accountable for any violations that result in economic losses [5]. - Any individual or entity that uses undisclosed information for trading or advising others to trade in the company's securities may face legal consequences [5]. - The document stipulates that in cases of conflict between this system and applicable laws or regulations, the latter will take precedence [5].

宁波美诺华药业股份有限公司 董事、高级管理人员所持公司股份及其变动管理制度 第一章 总 则 第一条 为加强对宁波美诺华药业股份有限公司（以下简称"公司"）董事、 高级管理人员持有及买卖本公司股票的管理，进一步明确办理程序，根据《中华 人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国证券法》（以下简 称"《证券法》"）《上海证券交易所股票上市规则》等法律、法规、规范性文件以 及《宁波美诺华药业股份有限公司章程》 （以下简称"《公司章程》"）的有关规定， 结合公司的实际情况，特制定本制度。 第二条 公司董事、高级管理人员，应当遵守本制度。 公司董事、高级管理人员就其所持股份变动相关事项作出承诺的，应当严格 遵守。 第三条 公司董事、高级管理人员所持本公司股份，是指登记在其名下和利用 他人账户持有的所有本公司股份。公司董事、高级管理人员从事融资融券交易的， 其所持本公司股份还包括记载在其信用账户内的本公司股份。 第二章 买卖本公司股票行为的申报 诺的，董事会秘书应当及时通知相关董事、高级管理人员。 第五条 公司董事、高级管理人员应当在下列时点或者期间内委托公司通过证 券交易所网站申报其个人、配偶、父母、 ...

宁波美诺华药业股份有限公司 年报信息披露重大差错责任追究制度 第一章 总 则 第一条 为提高宁波美诺华药业股份有限公司（以下简称"公司"）的规范运作水 平，确保公司年度报告信息（以下简称"年报信息"）披露的真实性、准确性、完整性 和及时性，加大对年报信息披露责任人的问责力度，提高年报信息披露的质量和透明度， 依据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所股票上市 规则》等法律、法规、规范性文件的相关规定以及《宁波美诺华药业股份有限公司章程》 （以下简称"《公司章程》"），结合公司实际情况，制定本制度。 第二条 本制度适用于公司董事、高级管理人员、公司控股股东、实际控制人、持 股 5%以上的股东、各部门及各下属子公司、分公司的负责人、财务负责人以及与年报 信息披露工作有关的其他人员。 第三条 本制度所指的责任追究是指年报信息披露工作中有关人员不履行或者不 正确履行职责、义务或其他个人原因，导致公司年报信息披露重大差错，对公司造成重 大经济损失或造成不良社会影响时的追究与处理。 本制度所称年报信息披露的重大差错，包括年度财务报告存在重大会计差错、其他 年度报告信息披露存在重大错误或重大遗漏、 ...

Core Viewpoint - The report highlights the financial performance and growth potential of Ningbo Menovo Pharmaceutical Co., Ltd. for the first half of 2025, showcasing significant increases in revenue and net profit, alongside strategic developments in the pharmaceutical industry [1][3]. Financial Performance - The company achieved a revenue of approximately 677.33 million yuan, representing an 11.42% increase compared to the same period last year [3]. - The total profit reached approximately 60.30 million yuan, marking a substantial increase of 117.00% year-on-year [3]. - The net profit attributable to shareholders was approximately 49.06 million yuan, reflecting a remarkable growth of 158.97% compared to the previous year [3]. - The net cash flow from operating activities was negative at approximately -6.93 million yuan, an improvement from -44.47 million yuan in the previous year [3]. Industry Overview - The global pharmaceutical market is projected to reach a size of 1.9 trillion USD by 2027, driven by economic growth, aging populations, and increasing health demands [5]. - The CDMO (Contract Development and Manufacturing Organization) market is expected to grow significantly, with a forecasted size of 124.3 billion USD by 2025 and 231 billion USD by 2030, reflecting a compound annual growth rate of 13.2% [5][6]. - The Chinese CDMO industry is anticipated to reach a market size of 104.88 billion yuan by 2024, with a continued growth trend into 2025 [6]. Business Strategy - The company focuses on a vertical integration strategy encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and formulations, aiming to enhance its competitive edge in the market [11][20]. - The company has established long-term partnerships with renowned pharmaceutical firms, enhancing its market presence and operational stability [10][11]. - The company is actively expanding its CDMO services, aiming to create a comprehensive service platform to support future growth [11]. Innovation and Development - The company is committed to technological innovation, with ongoing projects in continuous flow, enzyme catalysis, and automation to improve efficiency and reduce costs [16][17]. - The company has a robust pipeline of over 50 formulation projects, with several products already approved for market entry [14]. - The company is also exploring new therapeutic areas, including weight management and metabolic health, to diversify its product offerings [13]. Regulatory Environment - The regulatory landscape is evolving, with policies aimed at enhancing drug quality and innovation, which is expected to benefit the pharmaceutical industry in the long term [9][8]. - The company has successfully passed multiple audits and inspections from international regulatory bodies, ensuring compliance with global quality standards [20]. Market Position - The company is recognized as one of the top pharmaceutical manufacturers in China, with a strong reputation for quality and reliability in the production of specialty APIs and formulations [11][20]. - The company is strategically positioned to leverage the growing demand for high-quality generic and innovative drugs in both domestic and international markets [11].

| | | | | | | | 持有有限 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名称 | | | 持股比 股东性质 | | 持股 | | | 售条件的 | 质押、标记或冻结 | | | | | 例(%) | | 数量 | | | | 的股份数量 | | | | | | | | | 股份数量 | | | | 宁波美诺华控股集团有 | | | 境内非国有 | | | | | | | | 限公司 | | 法人 | | | | | | | | | 姚成志 | | | 境内自然人 | | 5.49 | 12,070,253 | | 0 | 无 | | 杜广娣 | | | 境内自然人 | | 0.93 | 2,054,623 | | 0 | 未知 | | 邱勇强 | | | 境内自然人 | | 0.79 | 1,732,798 | | 0 | 未知 | | 石建祥 | | | 境内自然人 | | 0.73 | 1,602,361 | | 0 | 未知 | | 尚杰 境内自然人 | | | | 0.72 | | 1,5 ...

宁波美诺华药业股份有限公司（以下简称"公司"）于 2025 年 8 月 15 日以 书面、电子邮件等方式向公司全体董事发出召开第五届董事会第十六次会议的通 知和会议材料。2025 年 8 月 26 日，公司第五届董事会第十六次会议在公司会议 室以现场结合通讯表决方式召开。本次会议由姚成志先生主持，会议应出席董事 集和召开符合《中华人民共和国公司法》等有关法律法规及《公司章程》《董事 会议事规则》的规定。 证券代码：603538 证券简称：美诺华 公告编号：2025-091 转债代码：113618 转债简称：美诺转债 宁波美诺华药业股份有限公司 第五届董事会第十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 二、董事会会议审议情况 （一）审议通过《2025 年半年度报告及摘要》 具体内容详见公司于上海证券交易所网（www.sse.com.cn）等指定信息披露 媒体同日披露的《2025 年半年度报告》及《2025 年半年度报告摘要》。 本议案已经公司董事会审计委员会全体成员审议通过，并同意 ...

证券代码：603538 证券简称：美诺华 公告编号：2025-092 转债代码：113618 转债简称：美诺转债 宁波美诺华药业股份有限公司 第五届监事会第十六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 宁波美诺华药业股份有限公司（以下简称"公司"）于 2025 年 8 月 15 日以 书面、电子邮件等方式向公司全体监事发出召开第五届监事会第十六次会议的通 知和会议材料。2025 年 8 月 26 日，公司第五届监事会第十六次会议在公司会议 室以现场结合通讯表决方式召开。本次会议由刘斯斌先生主持，会议应出席监事 集和召开符合《中华人民共和国公司法》等有关法律法规及《公司章程》的规定。 二、监事会会议审议情况 具体内容详见公司于上海证券交易所网（www.sse.com.cn）等指定信息披露 媒体同日披露的《2025 年半年度报告》及《2025 年半年度报告摘要》。 监事会审核并发表如下意见： 《2025 年半年度报告》及《2025 年半年度报告 摘要》的编制和审核程序符合法律、行政法规 ...